Novocure Q2 revenue beats, lifts 2026 outlook

Overview

• Global oncology firm's Q2 revenue rose 16% yr/yr, beating analyst expectations

• Company posted Q2 net loss of $15.7 mln

• Raised 2026 revenue and adjusted EBITDA guidance on patient growth, product launches

Outlook

• Novocure raises 2026 revenue guidance to $710 mln-$725 mln from $690 mln-$710 mln

• Company expects 2026 adjusted EBITDA of $0 mln-$15 mln, up from prior $(15) mln-$0 mln

• Guidance assumes mid-to-high single digit net revenue growth from Optune Gio

Result Drivers

• ACTIVE PATIENT GROWTH - Q2 revenue increase was primarily driven by 18% global active patient growth across indications

• NEW PRODUCT LAUNCHES - Revenue contribution from Optune Pax and Optune Lua, with Optune Pax receiving CE Mark and launching in Germany

• ONE-TIME BENEFITS - Q2 revenue included $2.8 mln in one-time benefits in the U.S., Germany and France

Company press release: ID:nBw9BdgSJa

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Novocure Ltd is $23.50, about 50.9% above its July 22 closing price of $15.57

Reuters Recommended Reads

• July 22 - Medpace Q2 revenue beats estimates on backlog conversion

• July 22 - Pfizer's prostate cancer drug combination gets US FDA priority review

• July 22 - GSK enters lung cancer drug market with early FDA nod for Jideytro

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)